These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 2226221)

  • 21. The role of newer antiarrhythmic drugs in the management of patients with ventricular arrhythmias.
    Cain ME
    Angiology; 1988 Jul; 39(7 Pt 2):668-83. PubMed ID: 3044200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mexiletine in refractory ventricular arrhythmias.
    Fenster PE; Kern KB
    Clin Pharmacol Ther; 1983 Dec; 34(6):777-84. PubMed ID: 6641093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical antiarrhythmic efficacy of mexiletine: a review.
    Kulbertus HE
    Acta Cardiol Suppl; 1980; (25):111-20. PubMed ID: 6990663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.
    Advani SV; Singh BN
    Drugs; 1995 May; 49(5):664-79. PubMed ID: 7601009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of quinidine in the mexiletine-quinidine interaction: electrophysiologic correlates of enhanced antiarrhythmic efficacy.
    Duff HJ; Rahmberg M; Sheldon RS
    J Cardiovasc Pharmacol; 1990 Nov; 16(5):685-92. PubMed ID: 1703588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency-dependent antiarrhythmic drug effects on postrepolarization refractoriness and ventricular conduction time in canine ventricular myocardium in vivo.
    Costard-Jäckle A; Franz MR
    J Pharmacol Exp Ther; 1989 Oct; 251(1):39-46. PubMed ID: 2795468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of disopyramide and mexiletine used alone and in combination for ventricular arrhythmias in patients with and without overt heart disease.
    Tanabe T; Takahashi K; Yoshioka K; Goto Y
    Int J Cardiol; 1991 Sep; 32(3):303-12. PubMed ID: 1724233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mexiletine in treatment of chronic ventricular refractary arrhythmias (author's transl)].
    Bellocci F; Ansalone G; Scabbia E; Santarelli P; Lucente M; Affinito V; Loperfido F; Zecchi P
    G Ital Cardiol; 1981; 11(4):488-97. PubMed ID: 6169580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiarrhythmic agents for chronic ventricular arrhythmias.
    Nestico PF; Morganroth J
    Compr Ther; 1987 Apr; 13(4):26-35. PubMed ID: 3105950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative antiarrhythmic efficacy of verapamil, 17-monochloracetylajmaline, mexiletine and amiodarone in patients with severe chagasic myocarditis: relation with the underlying arrhythmogenic mechanisms.
    Haedo AH; Chiale PA; Bandieri JD; Lázzari JO; Elizari MV; Rosenbaum MB
    J Am Coll Cardiol; 1986 May; 7(5):1114-20. PubMed ID: 3958370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mexiletine. Long-term efficacy and side effects in patients with chronic drug-resistant potentially lethal ventricular arrhythmias.
    Kerin NZ; Aragon E; Marinescu G; Faitel K; Frumin H; Rubenfire M
    Arch Intern Med; 1990 Feb; 150(2):381-4. PubMed ID: 2302013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of mexiletine in chronic ventricular arrhythmias compared with quinidine: a single-blind, randomized trial.
    Singh JB; Rasul AM; Shah A; Adams E; Flessas A; Kocot SL
    Am J Cardiol; 1984 Jan; 53(1):84-7. PubMed ID: 6362388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias.
    Morganroth J
    Am J Cardiol; 1987 Dec; 60(16):1276-81. PubMed ID: 3318368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of antiarrhythmic drugs.
    Lüderitz B; Mletzko R; Jung W; Manz M
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S48-52. PubMed ID: 1723119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electropharmacologic synergism with mexiletine and quinidine.
    Duff HJ; Kolodgie FD; Roden DM; Woosley RL
    J Cardiovasc Pharmacol; 1986; 8(4):840-6. PubMed ID: 2427827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the antiarrhythmic efficacy of mexiletine in patients with chronic ventricular arrhythmias.
    Van Durme JP
    Acta Cardiol Suppl; 1980; (25):121-5. PubMed ID: 6990664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiarrhythmic efficacy of penticainide and comparison with disopyramide, flecainide, propafenone and mexiletine by acute oral drug testing.
    Priori SG; Bonazzi O; Facchini M; Varisco T; Schwartz PJ
    Am J Cardiol; 1987 Nov; 60(13):1068-72. PubMed ID: 3118693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative cost-effectiveness analysis of quinidine, procainamide and mexiletine.
    Podrid PJ; Kowey PR; Frishman WH; Arnold RJ; Kaniecki DJ; Beck JR; Beshansky JR
    Am J Cardiol; 1991 Dec; 68(17):1662-7. PubMed ID: 1836102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low dose quinidine-mexiletine combination therapy versus quinidine monotherapy for treatment of ventricular arrhythmias.
    Giardina EG; Wechsler ME
    J Am Coll Cardiol; 1990 Apr; 15(5):1138-45. PubMed ID: 2179362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemodynamic effects of mexiletine.
    Shanks RG
    Am Heart J; 1984 May; 107(5 Pt 2):1065-71. PubMed ID: 6372422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.